[Remote] Business Development Director at Natera

San Carlos, California, United States

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Track record of leading and closing strategic collaboration and licensing agreements
8–10+ years of business development, strategic partnerships, or corporate development experience in biopharma, diagnostics, or life sciences
Demonstrated track record of structuring and closing deals in therapeutics, biomarkers, or AI/data-driven platforms
Strong scientific and commercial understanding of oncology, immunology, or related therapeutic areas
Familiarity with AI/ML in life sciences and its application to biomarker discovery, clinical trial optimization, and patient stratification
Bachelor’s in healthcare, life sciences, pharmacy or related field
MBA or Ph.D. is preferred
Industry background in diagnostics, software, life sciences, or private equity/venture capital
3+ years’ experience in BD, sales, investment banking or management consulting
Exceptional relationship-building, negotiation, and communication skills
Strong analytical ability, comfort with science and numbers
Strong attention to detail
Strong communication and leadership skills
Demonstrated ability to manage client relationships

Responsibilities

Identify, evaluate, and execute strategic partnerships with biopharma, biotech, and academic institutions
Lead negotiations, structure agreements, and drive to closure in collaboration with Legal, Finance, and executive leadership
Build a pipeline of opportunities by understanding evolving partner needs in biomarkers, clinical development, and precision medicine
Work closely with R&D, Product, and Medical Affairs to align external opportunities with internal strategy and capabilities
Represent Natera in negotiations with partners, customers, and suppliers

Skills

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free